A multinational research team led by Columbia University and the La Jolla Institute for Immunology has identified a novel viral target that could help combat the global resurgence of measles.
New images of one of the brain’s fastest-acting proteins—the kainate receptor—are providing critical clues that may lead to targeted therapies for epilepsy and other brain disorders.
A fat ‘shield’ that protects natural killer cells from self-destruction also allows some cancer cells to evade destruction by the immune system, researchers at Columbia University have found.
Twelve Columbia research teams have been awarded Columbia Life Science Accelerator pilot grants to develop technologies that aim to change the way patients are treated or diagnosed.
Even a brief exposure to addictive medications for surgery-related pain or anxiety can lead to long-term use, a study by Columbia researchers has found.
A new study from researchers at Columbia University is the first to quantitatively link psychological stress to graying hair in people and find that the process is reversible.
Three early-career scientists at VP&S—X. Shawn Liu (Physiology & Cellular Biophysics), Xuebing Wu (Medicine), and Nikhil Sharma (Molecular Pharmacology & Therapeutics)—are 2021 Paul Marks Scholars.
Spectacular images of a molecule that shuttles omega-3 fatty acids into the brain may open a doorway for delivering neurological therapeutics to the brain.
The new center builds on the school’s long-standing commitment to LGBTQ health and will study health among sexual and gender minority populations across the lifespan, with an emphasis on resilience.
The annual Vagelos Precision Medicine Pilot Grants have been awarded to five teams of VP&S researchers conducting innovative basic science, translational, and clinical research.